MBOT Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 25.86%, SMA50 23.77%, SMA200 -0.84%). The stock’s 14-day RSI is 69.19 (firm momentum), while the ATR of 0.17 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -45.18% below its high and over 104.8% above its low. Average 10-day trading volume of 1.06 million shares is below the 3-month average of 2.13 million, indicating normal recent market interest.

Microbot Medical Inc. (NASDAQ:MBOT) closed at $2.11 USD, gaining $0.01 (0.48%) from the previous close of $2.10. The stock is currently mid-range between its 52-week high and low $1.60 and $4.67. With a market capitalization of about $96.15 million, Microbot Medical Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.19). Key stats such as the average daily volume over the past year has been around 2.14 million shares, volume is running light vs its 52-week average. Headquartered in Hingham, MA, Microbot Medical Inc. operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Harel Gadot, the company employs approximately 20 people and listed since March 25, 1992. Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space.

Microbot Medical Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.07. This means the shares are trading above this model’s fair value.

Microbot Medical Inc. has 48.51 million shares outstanding. The public float is 45.55 million shares, elevated short interest at 17.14% of float. This equals 7.74 million shares. The short ratio is 3.44 days. Institutional investors hold 17.51% of the float. Insiders own 0.0%. Lewkowicz Leon holds 3.08 million shares, Shoham Moshe has 1.56 million shares and TSUKAMOTO ANN has 794.60 thousand shares.

Microbot Medical Inc. generated EPS of -$0.45 over the past year. Five-year average earnings growth is 15.51%. Wall Street analysts project EPS growth of 8.48% annually over the next five years. The latest quarter delivered EPS of -$0.04. The next quarter is forecast at -$0.08. Next year's EPS is expected at $41.28. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $5.00. The high target offers 468.72% upside. The low target suggests 136.97% downside. The mean target is $9.75. This offers 362.09% upside. Microbot Medical Inc. earnings surprise history is a mixed track record. The quarter that ended March 26, 2026, missed forecasts by -33.33%. The prior quarter beat by 16.67%. Over the last six quarters, Apple has recorded several small beats. These include 17.65% in November 13, 2024.

Microbot Medical Inc. trades at a P/E ratio of -10.81, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.83 suggesting the stock is closer to book value. The P/FCF stands at -7.35, also below market averages.

Our AI price prediction model suggests that Microbot Medical Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -7.58%, with price expected at $1.95 by May 18, 2026, within a range of $1.84 to $2.06 3-Month Outlook: Projected rise of 11.85%, reaching $2.36 by July 31, 2026, with a range of $2.25 to $2.46. 1-Year Outlook: Projected gain of 286.73%, with price at $8.16 by May 04, 2027, within a range of $1.83 to $13.88.

Microbot Medical Inc. (NASDAQ:MBOT) shares are flat 4.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Microbot Medical Inc. trading at a premium to the broader market with a P/E of -10.81. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.70, suggesting 359.72% upside. Our AI forecast model points to short-term weakness (-7.58% over two weeks), a medium-term rise (11.85% over three months), and a longer-term gain (286.73% over one year), with expected trading ranges indicating moderate volatility.